Literature DB >> 24456386

Guillain-Barré syndrome: subtypes and predictors of outcome from India.

Jayantee Kalita1, Usha K Misra, Gaurav Goyal, Moromi Das.   

Abstract

There is a paucity of large studies evaluating the subtypes of Guillain-Barré syndrome (GBS) and their outcome from Southeast Asia. We report cliniconeurophysiological subtypes of GBS and their correlation with triggering events and 3-month outcome from northern India. Three hundred and twenty eight consecutive patients with GBS were clinically evaluated, including their triggers, severity, autonomic involvement, cranial nerve palsy, and respiratory paralysis. Nerve conduction study (NCS) was repeated at 3 weeks if the initial study was normal. They were categorized into acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN), inexcitable motor nerve, and equivocal. Clinically, 204 (62.2%) patients had pure motor, 106 (32.3%) motor sensory, 16 (4.9%) Miller Fisher syndrome, and 2 (0.6%) pure sensory GBS. Based on NCS, 242 (73.8%) had AIDP, 44 (13.4%) AMAN, 15 (4.6%) AMSAN, 8 (2.4%) inexcitable motor nerves, and 27 (8.2%) equivocal GBS. AIDP patients were older, more common in summer, had lesser peak disability, and better outcome compared to those with AMAN. Eleven (3.4%) patients died and 48 (14.6%) had poor outcome at 3 months. The poor outcome was related to severity, dysautonomia, and inexcitable motor nerves. AIDP is the commonest variant of GBS in our study and has better outcome compared to AMAN.
© 2014 Peripheral Nerve Society.

Entities:  

Keywords:  AIDP; AMAN; AMSAN; GBS; Miller Fisher syndrome; nerve conduction study; outcome; pure sensory

Mesh:

Year:  2014        PMID: 24456386     DOI: 10.1111/jns5.12050

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  18 in total

Review 1.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

2.  Outcome of Guillain-Barre syndrome patients with respiratory paralysis.

Authors:  J Kalita; A Ranjan; U K Misra
Journal:  QJM       Date:  2015-10-15

3.  Tuberculosis and Guillain-Barre syndrome: A chance association?

Authors:  Srikant Mohta; Manish Soneja; Surabhi Vyas; Wasim Khot
Journal:  Intractable Rare Dis Res       Date:  2017-02

4.  Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.

Authors:  Gang Zhang; Qi Li; Rongrong Zhang; Xiao Wei; Junyi Wang; Xinyue Qin
Journal:  PLoS One       Date:  2015-07-22       Impact factor: 3.240

5.  Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India.

Authors:  Manisha Shrivastava; Shah Nehal; Navaid Seema
Journal:  Indian J Med Res       Date:  2017-02       Impact factor: 2.375

6.  Pulmonary Involvement in Patients with Guillain-Barré Syndrome in Subacute Phase.

Authors:  Meeka Khanna; Nidhi Rawat; Anupam Gupta; Madhu Nagappa; Arun B Taly; M R Rukmani; T N Sathyaprabha; Partha Haldar
Journal:  J Neurosci Rural Pract       Date:  2017 Jul-Sep

7.  Correlative study between C-reactive protein, clinical severity, and nerve conduction studies in Guillain-Barrè syndrome.

Authors:  Yosria A Altaweel; Sawsan Abdelaziz; Hala A Fathy; Shimaa AbdelBadea
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-04-25

8.  Variant Guillain-Barré Syndrome in a Patient with Non-Hodgkin's Lymphoma.

Authors:  R H Bishay; J Paton; V Abraham
Journal:  Case Rep Hematol       Date:  2015-08-11

Review 9.  Epidemiology of Peripheral Neuropathy: An Indian Perspective.

Authors:  Sweety Trivedi; Alak Pandit; Goutam Ganguly; Shyamal Kumar Das
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383

10.  Long-term prognosis of Guillain-Barré syndrome not determined by treatment options?

Authors:  Ying Wang; Wenjuan Lang; Yaqian Zhang; Xiaoyi Ma; Chunkui Zhou; Hong-Liang Zhang
Journal:  Oncotarget       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.